Related Experiment Video
Updated: Jan 25, 2026

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer
Published on: February 9, 2024
An advocacy victory: final USPSTF cervical cancer screening recommendations revised to include cotesting option
Diane Davis Davey1, Robert A Goulart2, Ritu Nayar3
1Department of Clinical Sciences, Associate Dean for Graduate Medical Education, University of Central Florida College of Medicine, Orlando, Florida.
Abstract:
The recent reversal of the US Preventive Services Task Force decision to drop cotesting (Papicolaou test + high-risk human papillomavirus test) as an option for cervical cancer screening in women aged 30 to 65 years from their recommendations for cervical cancer screening was directly attributed to advocacy efforts by professional organizations and individuals. This communication summarizes the pathology and laboratory medicine community's role in this advocacy effort by collaboration of all major US Pathology organizations, via the Cytopathology Education and Technology consortium.
Related Concept Videos
Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
Cancer
What is Cancer?
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
Robbers Cave
Cancer Prevention
Some...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

